To craft a compelling title, I need the specific condition the clinical trial is addressing. Could you please provide that information? For example, what disease, disorder, or health condition is the trial studying?

A Direct Comparison to Answer a Shared Problem

A new clinical trial at Stanford is asking whether modern migraine drugs might be the key to quieter days for millions of people with both tinnitus and migraine. The COMPACT-PM trial will compare two classes of preventive migraine medications to see if one is more effective at reducing the ringing, buzzing, or hissing in the ears that defines tinnitus. The study focuses on the role of a specific protein, calcitonin gene-related peptide (CGRP), which is active in migraine pathways and also found in the inner ear.

The Biological Link Between Migraine and Tinnitus

Approximately 15% of people worldwide experience tinnitus, and a history of migraine increases both the risk and severity of the condition. The common thread may be CGRP. This protein is a major player in migraine pain signaling, which is why a new generation of drugs—monoclonal antibodies and gepants—that block CGRP or its receptor have become effective migraine treatments. Importantly, CGRP and its receptors are also present in the cochlea’s hair cells, the spiral ganglion, and balance organs. Preclinical studies in mice show that altering CGRP levels can affect cochlear function. In humans, some older migraine preventants have been observed to reduce tinnitus burden. This trial will test if drugs specifically designed to target CGRP offer a more direct benefit for tinnitus linked to migraine.

Trial Design and Participant Experience

COMPACT-PM is a randomized, open-label, active-comparator controlled trial. In simple terms, 120 participants will be assigned by chance, like a coin flip, to one of two treatment groups. One group will receive anti-CGRP therapies (such as injectable monoclonal antibodies like erenumab or fremanezumab, or oral gepants like atogepant). The other group will receive conventional migraine preventives, which include tricyclic antidepressants like amitriptyline and nortriptyline, the SNRI venlafaxine, beta-blockers like propranolol, calcium channel blockers like verapamil, the angiotensin blocker candesartan, or the anticonvulsant topiramate.

A key feature is that there is no placebo group. The investigators state that withholding preventive treatment from migraine patients who need it would be unethical. Both groups receive standard, clinically indicated care. The specific medication within a group is chosen by the treating clinician based on the patient’s profile and insurance coverage.

Participants will be adults with bothersome tinnitus (a Tinnitus Functional Index score greater than 25) for at least six months and a physician-confirmed history of migraine. They must be candidates for starting or switching migraine preventive therapy. Over 24 weeks, the main measure is the change in the TFI score. Secondary assessments include hearing tests, balance evaluations, auditory brainstem response testing, and symptom diaries.

Current Status and Future Implications

The trial, funded by a philanthropic gift to Stanford University’s Department of Otolaryngology – Head & Neck Surgery, is not yet recruiting participants. It will be conducted at the Stanford Ear Institute.

For patients, the results could provide clearer guidance. If anti-CGRP therapies show superior benefit for tinnitus, it may support their use as a first-line option for patients with both conditions. If both classes perform similarly, it reinforces the value of conventional options, which are often more accessible. For researchers, the data will offer a detailed look at how CGRP modulation affects auditory function and tinnitus perception in humans, informing future studies on targeted inner ear treatments.

The COMPACT-PM trial moves beyond observing associations to directly testing a mechanistically driven hypothesis in a clinical setting. Its findings will add a substantive chapter to our understanding of the migraine-tinnitus connection and may point toward more precise treatment strategies.

This article is for informational purposes only. Consult a qualified professional for personalised advice.

Source:
Comparing Migraine Preventive Therapies vs. Anti-CGRP Therapies for Tinnitus in Patients With Migraine (COMPACT-PM) (ClinicalTrials.gov: NCT07655440)